2. Academic Validation
  3. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

  • J Med Chem. 1997 Nov 21;40(24):3979-85. doi: 10.1021/jm9704098.
S W Kaldor 1,  V J Kalish,  J F Davies 2nd,  B V Shetty,  J E Fritz,  K Appelt,  J A Burgess,  K M Campanale,  N Y Chirgadze,  D K Clawson,  B A Dressman,  S D Hatch,  D A Khalil,  M B Kosa,  P P Lubbehusen,  M A Muesing,  A K Patick,  S H Reich,  K S Su,  J H Tatlock
Affiliations

Affiliation

  • 1 Agouron Pharmaceuticals, Inc., San Diego, California 92121, USA.
PMID: 9397180 DOI: 10.1021/jm9704098
Abstract

Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and Antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent Enzyme inhibitor (Ki = 2 nM) and Antiviral agent (HIV-1 ED50 = 14 nM). An X-ray cocrystal structure of the enzyme-AG1343 complex reveals how the novel thiophenyl ether and phenol-amide substituents of the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively. In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. AG1343 (Viracept) has recently been approved for marketing for the treatment of AIDS.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z